Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs

Journal of Clinical Microbiology

Volumn 43, Issue 8, 2005, Pages 4186-4188

  Garcia Bujalance S ^a   Ladron De Guevara C ^a   Gonzalez Garcia J ^a   Arribas, J R ^a   Gutierrez A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTATION;

ANTI-HIV AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 23744493801     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.8.4186-4188.2005     Document Type: Article

References (14)

1. Derdelinckx, I., K. Van Laethem, B. Maes, Y. Schrooten, K. De Schouwe, S. De Wit, K. Fransen, S. García-Ribas, M. Moutschen, D. Vaira, G. Zissis, M. Van Ranst, E. Van Wijngaerden, and A. M. Vandamme. 2003. Performance of the VERSANT® HIV-1 Resistant Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes. FEMS Immunol. Med. Microbiol. 39:119-124.
2. Descamps, D., V. Calvez, G. Collin, A. Cecille, C. Apetrei, F. Damond, C. Katlama, S. Matheron, J. M. Huraux, and F. Brun-Vezinet. 1998. Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis J. Clin. Microbiol. 36:2143-2145.
3. Devereux, H. L., C. Loveday, and M. Youle. 2000. Substantial correlation between HIV-1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in heavily treated patients. AIDS 16:1025-1030.
4. EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15:309-320.
5. Hirsch, M. S., F. Brun-Vézinet, B. Clotet, B. Conway, D. R. Kuritzkes, R. T. D'Aquila, L. M. Demeter, S. M. Hammer, V. A. Johnson, C. Loveday, J. W. Mellors, D. M. Jacobsen, and D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37:113-128.
6. Kearney, M., S. Palmer, F. Maldarelli, C. Bixby, H. Bazmi, D. Rock, J. Falloon, R. Davey, R. Dewar, J. Metcalf, J. Mellors, and J. Coffin. 2004. Single-genome sequencing is more sensitive than standard genotype analysis for detection of HIV-1 drug resistance mutations. Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif.
7. Martinez-Picado, J., L. Sutton, M. Pia de Pasquale, A. V. Savara, and R. T. D'Aquila. 1999. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J. Clin. Microbiol. 37:2943-2951.
8. Rusconi, S., S. L. Catamancio, F. Sheridan, and D. Parker. 2000. A genotypic analysis of patients receiving zidovudine with either lamivudine, didanosine, or zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184, and 215. J. Clin. Virol. 19:135-142.
9. Schmit, J. C., L. Ruiz, L. Stuyver, K. Van Laethem, I. Vanderlinden, T. Puig, R. Rossau, J. Desmyter, E. De Clercq, B. Clotet, and A. M. Vandamme. 1998. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations J. Virol. Methods 73:77-82.
10. Servais, J., C. Lambert, E. Fontaine, J. M. Plesséria, I. Robert, V. Arendt, T. Staub, F. Schneider, R. Hemmer, G. Burtonboy, and J. C. Schmit. 2001. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy J. Clin. Microbiol. 39:454-459.
11. Stümer, M., B. Morgenstern, S. Staszewski, and H. W. Doerr. 2002. Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems. J. Clin. Virol. 25:65-72.
12. Stuyver, L., A. Wyseur, A. Rombout, J. Louwagie, T. Scarcez, C. Verhofstede, D. Rimland, R. F. Schinazi, and R. Rossau. 1997. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:284-291.
13. Van Laethem, K., K. Van Vaerenbergh, J. C. Schmit, S. Sprecher, P. Hermans, V. De Vrocy, R. Schuurman, T. Harrer, M. Witvrouw, F. Van Wijngaerden, L. Stuyver, M. Van Ranstt, J. Desmyter, E. De Clercq, and A. M. Vandamme. 1997. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J. Acquir. Immune Defic. Syndr. 22:107-118.
14. Villahermosa, M. L., G. Contreras, L. Perez-Alvarez, F. Bru, L. Medrano, E. Delgado, C. Colomo, M. Thomson, and R. Najera. 1998. Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors. Antiviral Ther. 3:221-227.